|Title||Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.|
|Publication Type||Journal Article|
|Year of Publication||2010|
|Authors||Chlebowski, RT, Anderson, GL, Gass, M, Lane, DS, Aragaki, AK, Kuller, LH, Manson, JAE, Stefanick, ML, Ockene, J, Sarto, GE, Johnson, KC, Wactawski-Wende, J, Ravdin, PM, Schenken, R, Hendrix, SL, Rajkovic, A, Rohan, TE, Yasmeen, S, Prentice, RL|
|Journal||JAMA : the journal of the American Medical Association|
|Date Published||2010 Oct 20|
In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported.